Gilead Announces Results from Study of Sovaldi ® for Retreatment of Chronic ... Business Wire (press release) Efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. Treatment response varies ... |
